GBT 009

Drug Profile

GBT 009

Alternative Names: GBT009

Latest Information Update: 12 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Garnet BioTherapeutics
  • Class Cell therapies
  • Mechanism of Action Cytokine stimulants; Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Scars

Most Recent Events

  • 12 Sep 2015 No recent reports of development identified - Phase-II for Scars (Prevention) in USA (Intradermal)
  • 28 Jan 2015 Garnet BioTherapeutics filed a friend of the court (amicus) brief at the Federal Circuit to protect its rights against Athersys in a patent interference
  • 26 Sep 2014 Garnet BioTherapeutics receives patent allowance for Cell Populations Which Co-Express CD49c and CD90 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top